

STANSBERRY RESEARCH CONFERENCE · LAS VEGAS · SEPTEMBER 2026

What if everything goes...right?

Andy & Landon Swan

Founders of LikeFolio · TradeSmith MegaTrends

LOUISVILLE, KENTUCKY • 2008


It started with a
dusty bottle of
bourbon.



\$250

WHAT WE FOUND LATER

Then the price followed.



Source: LikeFolio · monthly data, 2006–2022. Secondary-market price for Pappy Van Winkle 23-Year.

THE SAME BOTTLE · AT ITS PEAK, 2022

\$5,000

A 20× move on the secondary market

THE LESSON


Consumer demand moves first.
Stock prices follow.

It was true for a bottle of bourbon. It's true for stocks.

WHO WE ARE

We built a machine on that idea.

WHAT MAIN STREET IS SAYING



THE ENGINE

Swan AI

Millions of consumer signals a day, mapped to the stocks they move

WHAT COMES OUT



When it goes right, it looks like this.

HOME

May 2020 → Jul 2021



+611%

HOOD

Apr 2024 → Sep 2025



+556%

OKLO

Apr 2025 → Sep 2025



+461%

COIN


May 2023 → Nov 2024



+445%

AMD


Jun 2025 → May 2026



+227%

MegaTrends model portfolio · OKLO half position sold, remainder open. Past performance does not guarantee future results. Not investment advice.

Covid turned every living room into a project.



HOME

At Home Group

+611%

Bought · May 28, 2020 \$5.20
Sold · Jul 19, 2021 \$36.99


WHAT WE SAW

Spring 2020: Reddit and TikTok filled with furniture hauls. At Home mentions and web visits surged while the stock sat near \$5.

Price line: approximate monthly closes. Demand line illustrative. Past performance does not guarantee future results. Not investment advice.

Robinhood shot up the App Store charts.

Consumer demand HOOD stock price



HOOD

Robinhood Markets

+556%

Bought · Apr 1, 2024

\$19.51

Sold · Sep 24, 2025


\$128.11

WHAT WE SAW

Mentions up 193% year over year on a 30-day average. Social Heat Score at our rec: 80. Analysts still called it a meme.

Price line: approximate monthly closes. Demand line illustrative. Past performance does not guarantee future results. Not investment advice.

AI needs power. Main Street went searching for nuclear.



OKLO

Oklo Inc.

+461%

Bought · Apr 28, 2025 **\$24.98**
Sold half · Sep 24, 2025 **\$140.22**


WHAT WE SAW

Nuclear and data-center power searches exploded in late 2024, months before the stock moved. Social Heat Score at our rec: 79.

Price line: approximate monthly closes. Demand line illustrative. Past performance does not guarantee future results. Not investment advice.

After FTX collapsed, everyone moved their crypto to Coinbase.

Consumer demand COIN stock price



COIN

Coinbase

+445%


Bought · May 17, 2023 \$57.49
Sold · Nov 25, 2024 \$313.30

WHAT WE SAW

Searches for self-custody and Coinbase account setup surged while the headlines said crypto was dead.

Price line: approximate monthly closes. Demand line illustrative. Past performance does not guarantee future results. Not investment advice.

The AI buildout needed a second source for chips.



AMD

Advanced Micro Devices

+227%

Bought · Jun 16, 2025 **\$126.40**
Sold · May 6, 2026 **\$413.11**

WHAT WE SAW

Bullish divergence: consumer demand heating up faster than the stock price.
Social Heat Score at our rec: 88.

Price line: approximate monthly closes. Demand line illustrative. Past performance does not guarantee future results. Not investment advice.

◆ MEMBER MAIL

Real members. Real money.

“I bought 3,000 shares of OKLO at \$26 and sold them all at \$84 for a \$186,000 win.”

Ray P. · September 2025

+\$186,000

**“Made \$14K profit as of yesterday.
Your system is amazing.”**

Matt E. · on LEU

+\$14,000

**“My entire portfolio has been over
100% this past week.”**

David S. · HOOD & OKLO

+100%

Unsolicited member notes, 2025. Individual results — not typical. Past performance does not guarantee future results.

Then we act. Wall Street finds out last.



Google searches

Reddit threads

X posts

Searches

OKLO price

Mid 2024

Spring 2025

Searches explode in late 2024. The stock hasn't moved.

Swan AI

HEAT SCORE

79

STOCK PRICE

\$25

Demand running hot. Price still asleep.

OKLO

BUY ALERT

Oklo Inc. · sent to MegaTrends members

Bought · Apr 28, 2025

\$24.98

Sold half · Sep 24, 2025

\$140.22

THE RESULT

+461%

Search wave first. Price second.

Search-interest line illustrative. Past performance does not guarantee future results. Not investment advice.

THE EDGE

By the time it's on the news, we're already in.

MAIN STREET

consumer demand



WALL STREET

analyst attention



Every win started in this gap.

So does everything that comes next. (Illustrative.)

Four megatrends are lining up.


1 Next-Gen AI Disruptors

\$1T+

of insurance still run the old way

OSCR

LMND




2 Space Moonshots

200+

satellites photographing Earth daily

PL




3 The Machine Economy

One pilot

flying an entire drone swarm

PDYN




4 Memory Shortage

Sold out

AI data centers can't get enough

MRAM



The health insurer built on AI, taking on the biggest market in America.



OSCR

Oscar Health

MAIN STREET

93

WALL STREET


44

WHAT WE SEE

Up 2× since our original alert on May 15, 2025 — and we still love it. Member growth and app chatter keep accelerating.

Price: approximate monthly closes · demand line illustrative. Past performance does not guarantee future results. Not investment advice.

Oscar's consumer demand more than doubled from a year ago.



Source: LikeFolio consumer demand data, 90-day average vs. a year ago, through Sept. 18, 2026; daily closing prices. Not investment advice.

Oscar, a health insurer run on its own software, just posted a record first-half profit.

\$4.9B

Q2 revenue, up from \$2.9B a year ago

\$362M

Q2 profit, against a \$228M loss a year ago

2.96M

members, up 46% from a year ago

WHAT IT DOES

Oscar sells health insurance to individuals and families, mostly on the government's health insurance marketplaces. It runs the whole business on its own software.

WHAT JUST HAPPENED

Oscar raised its 2026 operating earnings outlook to \$500 million to \$700 million on Aug. 6. Membership reached 2.96 million, up 46%.

WHY IT MATTERS IN 2027

Oscar's CEO expects AI to speed up moves between full-time jobs, contract work, and retirement. People in between buy their own coverage, and that is Oscar's market.

"Our claims platform delivers 98.7% first pass accuracy and processes most claims in under 48 hours."

OSCAR'S CEO, ON THE AUG. 6 EARNINGS CALL

Sources: Oscar Health Q2 2026 results and earnings call, Aug. 6, 2026. Not investment advice.

The insurer built on AI, taking on a several-hundred-billion-dollar car market.



LMND

Lemonade

MAIN STREETWALL STREET


9539

WHAT WE SEE

AI handles quoting and claims. Car-insurance quote searches and app chatter climbing.

Price: approximate monthly closes · demand line illustrative. Past performance does not guarantee future results. Not investment advice.

Lemonade's consumer demand is still up 34% from a year ago, while its stock is down 22%.



Source: LikeFolio consumer demand data, 90-day average vs. a year ago, through Sept. 18, 2026; daily closing prices. Not investment advice.



Lemonade handles claims for about half what old-line insurers spend.

\$1.43B

premiums on the books, up 32%

5%

of premiums spent handling claims; the industry spends about 9%

+60%

car insurance premiums, to \$239M

WHAT IT DOES

Lemonade sells renters, home, pet, car, and life insurance through an app. AI quotes policies in minutes and pays many claims instantly.

WHAT JUST HAPPENED

Revenue rose 79% in the second quarter. Lemonade expects its first profitable quarter, on an adjusted basis, in Q4.

WHY IT MATTERS IN 2027


AI agents are starting to shop insurance for people. Lemonade tested those agents, and they pick Lemonade more often than its size predicts.

"...our competitors spend almost twice as much as we do on handling claims, and we're not done here by any means."

LEMONADE'S PRESIDENT AND CO-FOUNDER, ON THE JULY 29 EARNINGS CALL

Sources: Lemonade Q2 2026 shareholder letter and earnings call, July 29, 2026. Not investment advice.

The only daily photo of Earth, and the training data AI is missing.



PL

Planet Labs

MAIN STREET

92

WALL STREET


46

WHAT WE SEE

200+ satellites photograph the whole planet every day. AI models need exactly that data.

Price: approximate monthly closes · demand line illustrative. Past performance does not guarantee future results. Not investment advice.

Europe and Canada plan \$634 billion in defense spending this year. Planet's sales in its Europe region more than doubled.



Sources: NATO, Defence Investment of NATO Countries (2014-2026), July 2026; Planet Labs Q2 fiscal 2027 earnings call, Sept. 3, 2026. Not investment advice.



Planet's record quarter came with \$815 million in signed work.

\$116M

record quarterly revenue, up 58%

\$815M

signed business, half due within a year

\$4B

deals in its pipeline, the biggest it has seen

WHAT IT DOES

Planet runs a fleet of small satellites that photograph all of Earth's land every day. Governments and businesses pay for the images and the analysis.

WHAT JUST HAPPENED

Defense and intelligence sales grew more than 90% last quarter. The stock fell 25% on June 5, the day Planet filed to sell up to \$1.5 billion of new stock.

WHY IT MATTERS IN 2027


In August, a large AI developer renewed its contract with Planet to watch data center and chip plant construction from space.

"AI is all about the training data. Obviously, most generally to date, LLMs have trained off the text and other information on the Internet. That means they're largely blind to real-world information."

PLANET'S CEO, ON THE SEPT. 3 EARNINGS CALL

Sources: Planet Labs Q2 fiscal 2027 results and earnings call, Sept. 3, 2026; Planet 424B5 filing, June 5, 2026; daily closing prices, June 4 to 5, 2026. Not investment advice.

The software that lets one soldier fly a drone swarm.



PDYN

Palladyne AI

MAIN STREET

96

WALL STREET

35




WHAT WE SEE

Autonomy software for drones and robots.
Defense and robotics chatter surging.

Price: approximate monthly closes · demand line illustrative. Past performance does not guarantee future results. Not investment advice.

The Pentagon asked for \$54 billion for drones and other autonomous systems in 2027, four times its 2026 request.



Source: US Department of War FY2026 and FY2027 budget request overview books. \$39.2 billion of the 2027 request depends on separate funding legislation not yet passed. Not investment advice.



Palladyne's drone-swarm software won an Air Force contract and passed an Army field test.

+470%

Q2 revenue growth, to \$5.8M

\$24.6M

signed work as of June 30

\$4.2M

Air Force swarm contract, signed in July

WHAT IT DOES

Palladyne writes the AI software that lets one operator run a whole swarm of drones. Its SwarmOS software runs the swarm, and it builds its own Gremlin-X drone.

WHAT JUST HAPPENED

In an Army exercise, one operator used SwarmOS to control a whole group of drones. In August, Palladyne agreed to pair SwarmOS with targeting software from NORDA Dynamics, a Ukrainian-Estonian drone company.

WHY IT MATTERS IN 2027


The Army exercise showed SwarmOS works in the field, and the Air Force is paying for it. Palladyne expects formal bid requests in months, not years.

"For the most part, launching 1,000 drones today requires 1,000 soldiers."

PALLADYNE'S CEO, ON THE AUG. 6 EARNINGS CALL

Sources: Palladyne AI Q2 2026 results and earnings call, Aug. 6, 2026; Palladyne and NORDA Dynamics, Aug. 26, 2026; Pentagon 2027 budget request. Not investment advice.

The memory chip that never forgets, headed for the AI data center.



MRAM

Everspin Technologies

MAIN STREET

94

WALL STREET

41




WHAT WE SEE

MRAM keeps its data with the power off. AI data centers are short on memory and paying up.

Price: approximate monthly closes · demand line illustrative. Past performance does not guarantee future results. Not investment advice.

Memory chip sales are forecast to top \$1 trillion in 2027, driven by AI data centers, Everspin's next market.



Sources: WSTS Autumn 2025 and Spring 2026 forecasts; Everspin Q2 2026 earnings call. Not investment advice.



Everspin's memory chip keeps its data when the power goes out.

\$18.7M

record quarterly revenue, up 42%

\$40M

new subcontract on a US defense program

\$43.9M

cash, and no debt

WHAT IT DOES

Everspin makes MRAM, a memory chip that stores data magnetically. Nothing is lost in a power cut, so it runs in factory robots, power grids, planes, and satellites.

WHAT JUST HAPPENED

Factories, energy, aerospace, and defense drove record revenue on Aug. 5. In May, a short seller, Kerrisdale Capital, argued slot machines, not AI servers, are Everspin's biggest market.

WHY IT MATTERS IN 2027

Everspin plans new data center memory products over the next three years and signed an early deal with MaxLinear.

"we believe we can enable new persistent memory solutions for hyperscale cloud, AI infrastructure and enterprise Tier 1 customers."

EVERSPIN'S CEO, ON THE AUG. 5 EARNINGS CALL, ABOUT ITS NEW MAXLINEAR AGREEMENT

Sources: Everspin Q2 2026 results and earnings call, Aug. 5, 2026; Kerrisdale Capital, May 19, 2026. Not investment advice.




EXCLUSIVE BONUS

BONUS · AI BREAKTHROUGHS

The next longevity breakthrough may come from AI.

AI is cutting years off the search for new drugs.



15% to 80%

faster from discovery to first human trial

9

AI-found drugs on McKinsey's chart that reached human trials

By McKinsey's benchmark, big drugmakers take about four to six years to get a promising molecule into its first human trial. Longevity is where this pays off: diseases of aging need many new drugs, and AI makes each one faster and cheaper to find.

Source: McKinsey & Company, AI drug discovery: Focusing on what matters most, Sept. 21, 2026; company disclosures.

One trial result can move a stock 177% in a day.

— mRNA stock price



MRNA

Moderna

+517%

this year, through Sept. 23

WHAT HAPPENED

Merck and Moderna reported Aug. 19 that their personalized cancer vaccine cut melanoma recurrence in a late-stage trial.

Sources: Merck and Moderna, Aug. 19, 2026; daily closing prices through Sept. 23, 2026. Past performance does not guarantee future results. Not investment advice.



Anthropic's AI found a new CRISPR-like enzyme in 21 hours.

210M

tokens of AI work to find it, hidden in virus DNA

~950

AI agents working on the search

5 to 10 yrs

Anthropic's CEO says AI could help cure most diseases in that window

WHAT HAPPENED

Anthropic, the company behind Claude, has run a wet lab in the Bay Area since spring. Scientists there test what its AI finds.

WHAT AN AI WET LAB IS

AI proposes a new drug or gene tool. Scientists test it at the bench. The results train the AI for the next round, and each loop runs faster.

WHO ALREADY RUNS ONE

Absci and Recursion built their businesses on this loop: AI designs, their own labs test, and the data makes the next design better.

Sources: TechCrunch, Sept. 23, 2026; Absci and Recursion Q2 2026 earnings calls. Not investment advice.



Four stocks at the front of AI drug discovery.

Absci

ABSI

+179%

this year. Designs antibody drugs with AI and tests them in its own lab. Its lead drug targets hair loss.

Schrödinger

SDGR

+63%

this year. Sells drug-design software built on physics and AI, and co-invents drugs with partners.

Recursion

RXRX

1.5 years

from target to drug candidate, against about 4 years for the industry. Built on 50+ petabytes of biological data.

Generate Biomedicines

GENB

7 days

to test each new round of AI designs, down from three months. Its asthma drug is in two late-stage trials.

Sources: company disclosures; McKinsey & Company; daily closing prices through Sept. 23, 2026. Not investment advice.



Investors on X turned more bullish on all four this fall.

Recursion

RXRX

Bears went quiet

In June and July, investors on X argued about stock sales and hype. In our September sample, after the Tempus deal, none of the posts were bearish.

"Eventually they will try to buy rxrx or another hyperscaler will." (Reddit, July 4)

Schrödinger

SDGR

Talk took off

Posts jumped with the September rally, most of them about the run and AI drug discovery. Skeptics say its physics-based software is not AI.

"SDGR is pretty much the cleanest play in AI drug discovery." (Reddit, Sept. 17)

Absci

ABSI

Patients are watching

Much of the Reddit talk comes from hair-loss forums, where people follow ABS-201 as a treatment they might use. On X, investors call it an AI hair-growth stock.

"Absci crushed it with their phase 1 data today." (Reddit, June 24)

Generate Biomedicines

GENB


Nvidia's stake leads

Investors talk more about Nvidia's stake and the AI story than the asthma drug. Skeptics want proof that AI speeds up drug development.

"The x% that analysts keep noting for speeding up drug development is just completely made up." (Reddit, June 16)

Sources: LikeFolio review of Reddit and X posts, June 15 to July 15 and Aug. 25 to Sept. 24, 2026, with bots and news reposts removed. Not investment advice.

Searches for oral minoxidil, the hair-loss pill Absci's drug aims to match, are up fivefold since 2022.



Sources: Google Trends, US, weekly data through Sept. 20, 2026; Absci Q2 2026 earnings call, Aug. 11, 2026. Not investment advice.



Absci's first hair-growth results for its AI-designed drug come late this year.

\$25B+

US hair-loss market, per Absci's management

65+ days

half-life of one shot; 2 or 3 shots could cover six months

\$201M

cash on June 30, enough into the second half of 2028

WHAT IT DOES

Absci uses AI to design antibody drugs, then makes and tests them in its own lab. Its lead drug, ABS-201, targets hair loss and endometriosis.

WHAT JUST HAPPENED

Absci released its first safety data in June, and Lilly invested \$40 million. On Sept. 24, Absci moved its endometriosis trial start to mid-2027.

WHY IT MATTERS IN 2027

First hair-loss results come late this year, and full results in early 2027. Management puts the US hair-loss market at more than \$25 billion.

"Our partnership with Eli Lilly is tailored around the clinical development strategy for ABS-201 and does not confer rights to the program, which we plan to develop ourselves."


ABSCI'S CFO, ON THE AUG. 11 EARNINGS CALL

Sources: Absci Q2 2026 earnings call, Aug. 11, 2026; Absci, Sept. 24, 2026; Social Heat Score as of Sept. 28, 2026. Not investment advice.

Lilly paid Schrödinger \$57 million when it bought Ajax, a blood-cancer drug startup Schrödinger co-founded.

Schrödinger's Yearly Software Contract Value Is Up 86% Since 2021

Total annual contract value (ACV) as Schrödinger reports it, US\$ millions



Source: Schrödinger earnings releases, FY2021 to Q2 2026 · compiled September 28, 2026



Sources: Schrödinger earnings releases, FY2021 to Q2 2026; Schrödinger 8-K, June 29, 2026. Not investment advice.



Schrödinger's drug deals have paid it more than \$750 million since 2020.

+27%

growth in yearly software contract value, Q2

WHAT IT DOES

Schrödinger sells drug-design software built on physics and AI. It also co-invents drugs with partners and shares in the payoff.

\$750M+

earned from drug deals since 2020

WHAT JUST HAPPENED

It launched Bunsen, an AI helper that runs design work for chemists. On Sept. 9, it co-founded Tectora, a new company built on two of its drug programs.

\$419M

cash and securities on June 30

WHY IT MATTERS IN 2027


Bristol Myers Squibb expanded its use of the software. Schrödinger calls that a model for how big drugmakers will adopt it.

"...every computational chemist, drug hunter in the group, all of a sudden has a team of people that are helping them perform some of the routine tasks that end up taking up a lot of human time."

SCHRÖDINGER'S CEO, ON THE AUG. 5 EARNINGS CALL, ABOUT BUNSEN

Sources: Schrödinger Q2 2026 earnings call, Aug. 5, 2026; Schrödinger, Sept. 9, 2026. Not investment advice.

Drugmakers signed \$43 billion in AI drug-discovery partnerships in 2025, nearly four times 2024.



Source: DealForma, Jan. 2026. Values include milestone payments owed only if drugs succeed. Not investment advice.



Tempus now pays Recursion to license one of its AI models.

43%

median drop in colon polyps after three months on its drug

WHAT IT DOES

Recursion runs automated labs that test drugs on cells at huge scale. Its AI learns from the results to pick targets and design drugs.

50+ petabytes

of biological data, built to train AI

WHAT JUST HAPPENED

In September, Tempus agreed to pay Recursion \$12 million to license its RNA AI model. Roche's Genentech took Recursion's first neuroscience target into drug discovery.

\$557M

cash on June 30, enough into early 2028

WHY IT MATTERS IN 2027

More colon-polyp results, and early data on two more drugs, come in the first half of 2027.

"We are no longer just discussing the potential of our platform. We are demonstrating the ability of our AI-native product engine to generate differentiated programs and medicines."


RECURSION'S CEO, ON THE AUG. 5 EARNINGS CALL

Sources: Recursion Q2 2026 results and earnings call, Aug. 5, 2026; Recursion 8-K, Sept. 15, 2026; Social Heat Score as of Sept. 28, 2026. Not investment advice.

Sales of Tezspire, an asthma drug that blocks the same trigger as Generate's, grew elevenfold in three years.

Sales of Tezspire, an Asthma Drug That Blocks the Same Trigger as Generate's, Grew 11x in Three Years

Combined yearly Tezspire sales recorded by Amgen and AstraZeneca, US\$ millions



Source: AstraZeneca full-year results, FY2023 (2022 and 2023) and FY2025 (2024 and 2025) · compiled September 24, 2026



Source: AstraZeneca full-year results, FY2023 and FY2025 (combined Amgen and AstraZeneca sales). Not investment advice.



Generate's AI-designed asthma drug is in two late-stage trials.

Up to \$370M

in milestone payments per drug program from Amgen and Novartis

786

patients in each of two late-stage asthma trials

\$457M

cash on June 30, enough into the first half of 2028

WHAT IT DOES

Generate uses AI to design protein and antibody drugs from scratch. Amgen and Novartis pay it to design drugs for them.

WHAT JUST HAPPENED

Its asthma drug, given once every six months, skipped mid-stage trials and went straight to late-stage testing. Novartis moved a Generate-designed drug into its own pipeline.

WHY IT MATTERS IN 2027

Asthma trial enrollment should finish by the end of 2027. A second drug, built to prevent nerve damage from cancer treatment, reports early results in 2027.

"I think our fundamental premise is that we believe models will commoditize. I think where the moat lies is in data."

GENERATE'S CEO, AT THE BERNSTEIN HEALTHCARE FORUM, SEPT. 23

Sources: Generate Biomedicines Q2 2026 results, Aug. 6, 2026; Morgan Stanley and Bernstein investor conferences, Sept. 14 and 23, 2026. Not investment advice.

Five ideas. One board.

Five charts, all at the same point the bourbon was in 2008.

OSCR	NEXT-GEN AI DISRUPTORS	The health insurer built on AI.
LMND	NEXT-GEN AI DISRUPTORS	The AI insurer taking on the car market.
PL	SPACE MOONSHOTS	The only daily photo of Earth.
PDYN	THE MACHINE ECONOMY	One soldier, an entire drone swarm.
MRAM	MEMORY SHORTAGE	The memory chip that never forgets.

Not investment advice. Do your own research — or better, watch the data with us.

Your bonus board: four more ideas.

Four stocks using AI to find new drugs faster.

ABSI	LONGEVITY	The AI-designed hair-loss drug.
SDGR	AI DRUG DESIGN	The software drugmakers design on.
RXRX	AI WET LABS	The AI lab that finds drugs in under half the time.
GENB	AI DRUG DESIGN	New antibody designs tested in seven days.

Not investment advice. Do your own research, or better, watch the data with us.

BONUS · MEGATRENDS MEMBERS SAW IT FIRST

 EXCLUSIVE BONUS

MegaTrends members saw these in May. One is up 98% since.

MAY 21 · THE LONGEVITY REPORT				MAY 29 · BIG PHARMA: THE NEXT AI SUPERCYCLE			
		PEAK	NOW			PEAK	NOW
DXCM	Dexcom	+28% Aug. 21	+21%	SDGR	Schrödinger (bonus pick)	+102% Sept. 22	+98%
LTH	Life Time	+39% Aug. 24	+19%	TEM	Tempus AI	+69% Sept. 28	+69%
WST	West Pharmaceutical	+19% Sept. 23	+18%				
DAR	Darling Ingredients	+18% Aug. 18	+5%				

It is still early. Catch up here, and stay ahead of the next trends we find:

July: Memory Shortage August: Power Grab September: The Memory Buildout

Peak: best price since the feature date. Now: 11:30 a.m. ET, Sept. 28, 2026. Watchlist features, not positions. Past results do not guarantee future results.

ONE LAST THING

Most of you are probably already with us.

If you want to see what Main Street is buying next:

Click here to join MegaTrends →

<https://secure.tradesmith.com/?cid=MKT847128&eid=MKT885670>

→ Get every new idea the day our data flags it

“Main Street talks. We listen. Wall Street finds out last.”

Thank you — Andy & Landon